---
title: "Basecare Wins NMPA Class III Approval for Gems Embryo Culture Medium"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286258287.md"
description: "Suzhou Basecare Medical Corp. Ltd. has received NMPA Class III approval for its Gems cleavage embryo culture medium, enhancing its portfolio of certified products. This medium, developed with expertise from the Sydney IVF Center, aims to improve embryo stress resistance and support in assisted reproduction. With this approval, all four core products in the Gems series are now certified, creating a comprehensive embryo culture system for fertility specialists. The company focuses on assisted reproductive technologies and has a market cap of HK$506M."
datetime: "2026-05-13T11:44:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286258287.md)
  - [en](https://longbridge.com/en/news/286258287.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286258287.md)
---

# Basecare Wins NMPA Class III Approval for Gems Embryo Culture Medium

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Suzhou Basecare Medical Corp. Ltd. Class H ( (HK:2170) ) has shared an announcement.

Suzhou Basecare Medical Corporation Limited has obtained National Medical Products Administration approval in China for its independently developed Gems cleavage embryo culture medium as a Class III medical device. The product had already secured CE, U.S. FDA and Australian TGA certifications, reflecting its established international regulatory standing.

Developed using three decades of technological expertise from the Sydney IVF Center and more than a decade of overseas clinical validation, the upgraded medium is designed to improve early embryo stress resistance and developmental support for assisted reproduction in China. With this approval, all four core primary culture products in the Gems series are now fully certified, completing a sequential culture media portfolio and creating a closed-loop full-cycle embryo culture system that broadens clinical options for fertility specialists.

**More about Suzhou Basecare Medical Corp. Ltd. Class H**

Suzhou Basecare Medical Corporation Limited is a China-based medical device company focused on assisted reproductive technologies and embryo culture solutions. Its product portfolio includes the Gems series of embryo culture media, targeting fertility clinics and reproductive medicine centers in China and internationally.

**Average Trading Volume:** 108,127

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$506M

Learn more about 2170 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [02170.HK](https://longbridge.com/en/quote/02170.HK.md)
- [562600.CN](https://longbridge.com/en/quote/562600.CN.md)
- [159883.CN](https://longbridge.com/en/quote/159883.CN.md)
- [512170.CN](https://longbridge.com/en/quote/512170.CN.md)
- [159898.CN](https://longbridge.com/en/quote/159898.CN.md)

## Related News & Research

- [Broncus shareholders back all AGM resolutions, update articles of association](https://longbridge.com/en/news/286439966.md)
- [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md)
- [DOJ Launches Criminal Probe Into Blue State Hospital](https://longbridge.com/en/news/286157785.md)
- [Ventripoint's VMS+ (TM) 4.0 Submitted for Regulatory Approval in China by Lishman Global Inc.](https://longbridge.com/en/news/284379502.md)
- [16:45 ETSetPoint Medical to Participate at the Bank of America Health Care Conference](https://longbridge.com/en/news/285120480.md)